AVTX Stock Overview
A clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Avalo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.00 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$3.39 |
| Beta | 0.88 |
| 1 Month Change | -20.63% |
| 3 Month Change | -40.30% |
| 1 Year Change | -65.77% |
| 3 Year Change | -99.63% |
| 5 Year Change | -99.95% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007
Aug 01Avalo Therapeutics announces one-for-twelve reverse stock split
Jul 06Is Cerecor (NASDAQ:CERC) A Risky Investment?
Aug 10
What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?
Mar 10Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?
Jan 18Shareholder Returns
| AVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.7% | 0.1% | 1.7% |
| 1Y | -65.8% | -11.7% | 11.6% |
Return vs Industry: AVTX underperformed the US Biotechs industry which returned -12.5% over the past year.
Return vs Market: AVTX underperformed the US Market which returned 11.5% over the past year.
Price Volatility
| AVTX volatility | |
|---|---|
| AVTX Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: AVTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AVTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 23 | Garry Neil | www.avalotx.com |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.
Avalo Therapeutics, Inc. Fundamentals Summary
| AVTX fundamental statistics | |
|---|---|
| Market cap | US$43.31m |
| Earnings (TTM) | US$73.01m |
| Revenue (TTM) | US$441.00k |
Is AVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTX income statement (TTM) | |
|---|---|
| Revenue | US$441.00k |
| Cost of Revenue | US$20.80m |
| Gross Profit | -US$20.36m |
| Other Expenses | -US$93.37m |
| Earnings | US$73.01m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.74 |
| Gross Margin | -4,616.55% |
| Net Profit Margin | 16,556.01% |
| Debt/Equity Ratio | 0% |
How did AVTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/01 17:54 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avalo Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Edward White | H.C. Wainwright & Co. |